Recent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma
The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated
read more
May is Ocular Melanoma Awareness Month
Ocular (uveal) melanoma is a rare but dangerous disease, and only a small number of doctors in the United States treat it. At Texas Retina, we have been caring for ocular melanoma
read more Getting to Know Ocular Oncologist Timothy S. Fuller, MD
May is Ocular Melanoma Awareness Month. Ocular (uveal) melanoma is a rare but dangerous disease, and only a small number of doctors in the United States treat it. At Texas Retina Associates,
read more May is Ocular Melanoma Awareness Month
Although rare, ocular (uveal) melanoma is the most common primary cancer of the eye in adults with an estimated 2,000 – 3,000 new cases in the United States each year. This type
read more Ocular (Uveal) Melanoma and Biopsy – the “Why” and “How” of It
By Timothy Fuller, MD, Ocular Oncologist With the diagnosis of ocular (uveal) melanoma comes the very real risk of metastatic disease, or “spread” of the cancer to other parts of the body.
read more Texas Retina Associates Participating in New Phase II Clinical Trial for Choroidal Melanoma
Texas Retina Associates is pleased to announce its participation in a groundbreaking new Phase II clinical trial for the treatment of small choroidal (ocular) melanoma. Together with Aura Biosciences, we are investigating
read more
Getting to Know Timothy S. Fuller, MD
Timothy S. Fuller, MD, is one of three Dr. Fullers at Texas Retina Associates. In August 2016, he joined his father Dwain Fuller, MD, and older brother Christopher Fuller, MD, at our
read more